Biotechnology

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

September 8, 2021 7:05 AM

Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms today announced it is formally beginning the process towards an Investigational New Drug ("IND") application filing with the Food and Drug Administration ("FDA") with its...

Read more

Nanalysis Scientific Corp. to Present at the 10th Annual Gateway Conference on September 9, 2021

September 7, 2021 3:55 PM

CALGARY, AB / ACCESSWIRE / September 7, 2021 / Nanalysis Scientific Corp. (TSXV:NSCI)(OTCQX:NSCIF) has been invited to present at the 10th Annual Gateway Conference, which is being held virtually on September 8-9, 2021. Nanalysis CEO, Mr. Sean Krakiwsky, is scheduled to present on Thursday, September ­­9 at 11 a.m. Mountain time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available...

Read more

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

September 7, 2021 8:05 AM

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq...

Read more

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period

September 7, 2021 7:05 AM

Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECHTM-processed cannabidiol...

Read more

BioLargo Launches PFAS Testing and Treatment System Selection Program

September 2, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / September 2, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it has launched a new service offering to test customer water to determine PFAS contamination levels and advise on appropriate treatment equipment options to meet federal, state and local regulatory requirements. The program offers peace of mind and...

Read more

M2Bio Sciences Appoints Dr. Riyad Domingo as Chief Innovation Officer

September 2, 2021 8:30 AM

CAPE TOWN, SA / ACCESSWIRE / September 2, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following remarkable update: M2Bio SciencesTM is delighted to announce the appointment of Dr. Riyad Domingo as Chief Innovation Officer effective immediately. Dr. Domingo holds a PhD in Medical...

Read more

Hemogenyx Pharmaceuticals PLC Announces U.S. Approval of Monoclonal Antibody Patent

September 2, 2021 2:00 AM

LONDON, UK / ACCESSWIRE / September 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office. The patent was issued on 31 August 2021 as Patent Number US...

Read more

Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer

September 1, 2021 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including more...

Read more

Thermic Science Completes Prototype Designs and Component Specifications for its Retail Thermic Infrared Portable Heaters, Moves Forward North American Manufacturing Contracts, Hi-Tech WIFI App, Remote Control Thermostat, for the North American Retail Consumer

August 31, 2021 8:35 AM

NASHVILLE, TN / ACCESSWIRE / August 31, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN:A1W61J)(ISIN:US29271J1097, (OTC:ENDO), is pleased to announce the company has successfully completed its prototype designs and component specifications for the Thermic Science Infrared Portable Heater product line and completing its first North American Manufacturing Contracts in the...

Read more

Ensysce Biosciences Sets September 2021 Conference Schedule

August 31, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 31, 2021 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, is scheduled to participate at the following industry and financial conferences during September 2021: 10th Annual Gateway Conference Date and Time: Held virtually...

Read more

Gemina Labs Announces Research and Development Appointments

August 30, 2021 12:40 PM

VANCOUVER, BC / ACCESSWIRE / August 30, 2021 / Gemina Laboratories Ltd. (CSE:GLAB) (the "Company" or "Gemina") is pleased to announce several key hires within our Research and Development team. Research and Development Appointments Within the Research and Development group, the Company has expanded its development competencies with the appointment of Elliot Hong as Vice President of Product Development. Mr. Hong is a mechanical engineer with...

Read more

EV Biologics Updates on NFT Warrant Dividend Distribution

August 30, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution. The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC. As previously announced, YECO's shareholders-of-record on July 30, 2021, will receive a Warrant to exercise their right to accept...

Read more

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

August 26, 2021 4:01 PM

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL1,2,3...

Read more

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

August 26, 2021 7:30 AM

Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORONTO, ON / ACCESSWIRE / August 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on a Phase 2/3 clinical study evaluating the...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

August 25, 2021 10:45 AM

MOUNT VERNON, NY / ACCESSWIRE / August 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

BioLargo's Tonya Chandler to Present with Expert Panel at Sustain SoCal's Water Solutions 6 Web Conference on August 26, 2021

August 25, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / August 25, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced its participation in Water Solutions 6, the sixth annual water innovation focused conference run by Sustain SoCal, a leading cleantech industry advocacy organization in Southern California (https://sustainsocal.org). The event takes place on August 26, 2021...

Read more

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

August 24, 2021 9:00 AM

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor (CTGF) inhibitor the Company is developing for the treatment of idiopathic...

Read more

Dr. AnnaRx(TM) Launching CBD & CBN Nutraceutical Line

August 24, 2021 8:45 AM

CAPE TOWN, SA / ACCESSWIRE / August 24, 2021 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update: The Dr AnnaRxTM CBD and CBN range has been finalized. The four initial products to be released are: CBD Energy: Amplify energy and focus to keep you productive throughout the day. CBD...

Read more

ITOCO Welcomes Mr. Erik Gordillo Enamorado as Project Coordinator Carbon Credits and Chief Agricultural Liaison

August 24, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / August 24, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Erik Gordillo Enamorado has joined ITOCO as Project Coordinator Carbon Credits and Chief Agricultural Liaison. Mr. Enamorado is an Agronomist Engineer with a specialty in Agricultural Economics from the Universidad Autónoma Chapingo, Texcoco, Mexico. His studies focused on developing expertise in Agribusiness, Agriculture, and sustainable...

Read more

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th

August 23, 2021 7:00 PM

TUCSON, AZ / ACCESSWIRE / August 23, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, is excited to be one of 5 medical companies selected to present at the 2021 Annual Southwest Venture Madness competition. There were over 120 companies who submitted applications for this year's competition. The companies who submitted applications fell...

Read more